RYTM · Insider trading · 13F holders · Congress trades
Rhythm Pharmaceuticals, Inc. (RYTM)
Who is buying and selling RYTM: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 28
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $28.8M
- Congress trades, 12 months
- 0
RYTM at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 6 RYTM insiders filed 6 sales worth $28.8M on SEC Form 4, and no open-market purchases; 6 of the sales were pre-planned under Rule 10b5-1.
- 28 13F filers hold RYTM among their 50 largest positions, worth $2.6B combined, including Peter Kolchinsky, Joseph Edelman, Julian and Felix Baker and Stanley Druckenmiller. The biggest bets by portfolio weight are NEXTBio Capital Management LP (6.7%), Peter Kolchinsky (6.4%) and Joseph Edelman (4.5%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.
- No member of Congress has disclosed a trade in RYTM.
- RYTM last closed at $93.07 on Oct 29, 2026.
RYTM insider trading
Between Aug 1, 2026 and Oct 29, 2026, 6 RYTM insiders filed 6 sales worth $28.8M on SEC Form 4, and no open-market purchases; 6 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Meeker David P | President and CEO, Director | Sale10b5-1 | 50,000 | $102.67 | $5.1M | SEC |
| Sep 1, 2026 | Smith Hunter C | Chief Financial Officer | Sale10b5-1 | 62,774 | $105.46 | $6.6M | SEC |
| Aug 17, 2026 | Garfield Alastair | Chief Scientific Officer | Sale10b5-1 | 7,763 | $117.57 | $913K | SEC |
| Aug 17, 2026 | Shulman Joseph | Chief Technical Officer | Sale10b5-1 | 5,079 | $119.75 | $608K | SEC |
| Aug 14, 2026 | Lee Jennifer Kayden | EVP, Head of North America | Sale10b5-1 | 75,834 | $117.38 | $8.9M | SEC |
| Aug 14, 2026 | Mazabraud Yann | EVP, Head of International | Sale10b5-1 | 57,000 | $116.15 | $6.6M | SEC |
Who owns RYTM? Hedge funds and superinvestors
28 13F filers hold RYTM among their 50 largest positions, worth $2.6B combined, including Peter Kolchinsky, Joseph Edelman, Julian and Felix Baker and Stanley Druckenmiller. The biggest bets by portfolio weight are NEXTBio Capital Management LP (6.7%), Peter Kolchinsky (6.4%) and Joseph Edelman (4.5%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.
Superinvestors holding RYTM: Peter Kolchinsky 6.4% · Joseph Edelman 4.5% · Julian and Felix Baker 3.1% · Stanley Druckenmiller 0.5%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Peter KolchinskyHedge fund | 6.4% | $740.2M | 6,666,837 | +0.0% shares | Q2 2026 |
| Julian and Felix BakerHedge fund | 3.1% | $622.3M | 5,604,483 | +0.0% shares | Q2 2026 |
| Joseph EdelmanHedge fund | 4.5% | $287.2M | 2,586,295 | +9.0% shares | Q2 2026 |
| Westfield Capital Management Co LPAsset manager | 0.8% | $245.2M | 2,208,595 | +14.5% shares | Q2 2026 |
| Checkpoint Capital L.P.Hedge fund | 33.8% | $131.7M | 1,186,000 | -3.4% shares | Q2 2026 |
| Siren, L.L.C.Investment manager | 2.6% | $126.2M | 1,136,275 | +56.6% shares | Q2 2026 |
| Rock Springs Capital Management LPHedge fund | 3.8% | $76.9M | 692,598 | +0.4% shares | Q2 2026 |
| Integral Health Asset Management, LLCHedge fund | 2.5% | $61.1M | 550,000 | -8.3% shares | Q2 2026 |
| Sofinnova Investments, Inc.Hedge fund | 2.4% | $45.3M | 408,027 | -9.3% shares | Q2 2026 |
| Braidwell LPHedge fund | 1.6% | $42.3M | 381,128 | +22.7% shares | Q2 2026 |
| Orbimed Advisors LLCHedge fund | 0.7% | $35.9M | 322,900 | +2.8% shares | Q2 2026 |
| Silverarc Capital Management, LLCHedge fund | 3.8% | $34.6M | 311,461 | +1.8% shares | Q2 2026 |
| Stanley DruckenmillerFamily office | 0.5% | $22.6M | 203,618 | — | Q2 2026 |
| First Turn Management, LLCInstitutional asset manager | 1.8% | $17.1M | 154,018 | New | Q2 2026 |
| Nicholas Investment Partners, LPInvestment manager | 1.0% | $15.5M | 139,270 | — | Q2 2026 |
| ADAR1 Capital Management, LLCHedge fund | 0.7% | $15.1M | 136,158 | -35.6% shares | Q2 2026 |
| NEXTBio Capital Management LPHedge fund | 6.7% | $14.6M | 131,758 | +4.5% shares | Q2 2026 |
| Logos Global Management LPHedge fund | 0.6% | $13.9M | 125,000 | -72.2% shares | Q2 2026 |
| Opaleye Management Inc.Hedge fund | 1.2% | $13.6M | 122,500 | -0.4% shares | Q2 2026 |
| PFM Health Sciences, LPHedge fund | 1.0% | $11.3M | 101,550 | -25.7% shares | Q2 2026 |
| First Light Asset Management, LLCHedge fund | 0.6% | $9.5M | 85,765 | -1.6% shares | Q2 2026 |
| Sphera Funds Management Ltd.Hedge fund | 1.3% | $8.9M | 80,400 | — | Q2 2026 |
| Atom Investors LPHedge fund | 0.7% | $8.2M | 73,465 | — | Q2 2026 |
| Blue Owl Capital Holdings LPHedge fund | 1.0% | $6.8M | 61,455 | +0.0% shares | Q2 2026 |
| Nan Fung Group Holdings LtdInvestment manager | 4.1% | $5.5M | 49,120 | +0.0% shares | Q2 2026 |
| Exome Asset Management LLCHedge fund | 2.2% | $3.6M | 32,209 | -20.6% shares | Q2 2026 |
| AlphaCentric Advisors LLCMutual fund manager | 0.9% | $1.0M | 9,449 | +1.6% shares | Q2 2026 |
| Liberty Mutual Group Asset Management Inc.Asset manager | 0.0% | $98K | 880 | -95.7% shares | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 28). Screen RYTM in the grand portfolio →
RYTM stock trades by members of Congress
No member of Congress has disclosed a trade in RYTM.
RYTM questions and answers
Are insiders buying RYTM stock?
Between Aug 1, 2026 and Oct 29, 2026, 6 RYTM insiders filed 6 sales worth $28.8M on SEC Form 4, and no open-market purchases; 6 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own RYTM?
28 13F filers hold RYTM among their 50 largest positions, worth $2.6B combined, including Peter Kolchinsky, Joseph Edelman, Julian and Felix Baker and Stanley Druckenmiller. The biggest bets by portfolio weight are NEXTBio Capital Management LP (6.7%), Peter Kolchinsky (6.4%) and Joseph Edelman (4.5%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.
Has Congress traded RYTM?
No member of Congress has disclosed a trade in RYTM.
Who is the largest holder of RYTM?
Among 13F filers, Peter Kolchinsky reports the largest RYTM position, $740.2M (6,666,837 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is NEXTBio Capital Management LP's: 6.7% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.